EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rituximab for the Management of an Australian Cohort of Treatment Refractory Mucous Membrane Pemphigoid

Bronte Jeffrey iD, Mark Schifter, Elizabeth Arena, Emily Sullivan, Stephanie Rose, David Joo, David Campbell, Suzanne Culican, David McDonald, Ming Wei Lin

Australasian Journal of Dermatology · 2025-08 · 66 (5)

DOI: 10.1111/ajd.14523 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Australasian Journal of Dermatology, online erschienen am 16.05.2025. Verfasst von Bronte Jeffrey und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Westmead Hospital, Sydney, Australia. Hauptthemen laut MEDLINE: Rituximab, Pemphigoid, Benign Mucous Membrane, Immunologic Factors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mucous membrane pemphigoid (MMP) has a broad range of clinical manifestations, from relatively benign self‐limiting oral lesions to significant scarring (cicatrizing) of the oral, nasal and ocular tissues with severe functional impairment and morbidity. European Guidelines recommend rituximab as only second‐ or third‐line therapy, based on the extent/severity of the disease; however, there are no established clinical or serological markers that are predictive of severe disease warranting the use of agents such as rituximab.

Methods

Retrospective cross‐sectional cohort study of patients who met the following criteria: (1) biopsy confirmed MMP; (2) required a steroid‐sparing immunosuppressant therapy, that is, mycophenolate and/or rituximab and (3) at least 6 months of clinical monitoring. The primary end point was complete or partial remission.

Results

Of the 45 patients who met the criteria, 12 (27%) had sustained remission with mycophenolate. Thirty‐three (73%) patients had either relapsed or were refractory to mycophenolate and, therefore, were treated with rituximab. Of those who received rituximab, 97% achieved a complete remission after a single course (1 g given intravenously on Days 1 and 14), but 24% needed repeat treatment. The detection rates of key circulating antibodies, namely skin basement membrane antibodies (SBMA), BP180/230, collagen VII and laminin 332, were low and did not identify those patients refractory to mycophenolate. Adverse reactions, including infectious complications, were minimal in both patient groups.

Conclusion

In our study of mostly localised mucosal MMP patients, there was an excellent response to a single course of treatment with rituximab, with durable remission and no major adverse complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabPemphigoid, Benign Mucous MembraneImmunologic FactorsHumansFemaleMaleRetrospective StudiesCross-Sectional StudiesAgedMiddle AgedAustraliaAged, 80 and overImmunosuppressive AgentsAdultMycophenolic AcidRemission Induction

Stichwörter der Autor:innen

biomarkersbullousoralpemphigoidrituximab

Substanzen

RituximabImmunosuppressive AgentsMycophenolic AcidImmunologic Factors

Autor:innen und Institutionen

  • Department of Clinical Immunology, Westmead Hospital, Sydney, Australia.
  • St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Department of Immunopathology, NSWHP-ICPMR, Westmead Hospital, Sydney, Australia.
  • Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Department of Oral Medicine, Westmead Hospital, Sydney, Australia.
  • Centre for Immunology and Allergy Research, Westmead Institute of Medical Research, Sydney, Australia.

ORCID-Profile: Bronte Jeffrey

Zitieren

APA

Jeffrey, B., Schifter, M., Arena, E., Sullivan, E., Rose, S., Joo, D., Campbell, D., Culican, S., McDonald, D., & Lin, M. W. (2025). Rituximab for the Management of an Australian Cohort of Treatment Refractory Mucous Membrane Pemphigoid. Australasian Journal of Dermatology, 66(5). https://doi.org/10.1111/ajd.14523

Vancouver

Jeffrey B, Schifter M, Arena E, Sullivan E, Rose S, Joo D, et al. Rituximab for the Management of an Australian Cohort of Treatment Refractory Mucous Membrane Pemphigoid. Australasian Journal of Dermatology. 2025;66(5). doi:10.1111/ajd.14523

BibTeX
@article{Jeffrey2025,
  author = {Jeffrey, Bronte and Schifter, Mark and Arena, Elizabeth and Sullivan, Emily and Rose, Stephanie and Joo, David and Campbell, David and Culican, Suzanne and McDonald, David and Lin, Ming Wei},
  title = {Rituximab for the Management of an Australian Cohort of Treatment Refractory Mucous Membrane Pemphigoid},
  journal = {Australasian Journal of Dermatology},
  year = {2025},
  volume = {66},
  number = {5},
  doi = {10.1111/ajd.14523}
}
Kostenlos starten →